Targeting E3 Ubiquitin Ligases in Post-Traumatic Osteoarthritis: Therapeutic Opportunities and Pharmacological...

Post-traumatic osteoarthritis (PTOA) is a rapidly progressing joint disorder initiated by acute injury, characterized by persistent inflammation, chondrocyte dysfunction, and extracellular matrix (ECM) degradation. Despite its clinical burden, effective disease-modifying therapies are lacking. Increasing evidence suggests that the ubiquitin-proteasome system, particularly E3 ubiquitin ligases, plays a pivotal role in regulating key pathogenic pathways involved in PTOA and represents a potentially druggable regulatory axis. In this review, we provide a comprehensive overview of the emerging roles of E3 ubiquitin ligases in PTOA, highlighting their involvement in inflammatory signaling, chondrocyte fate regulation, and cartilage matrix remodeling. We further integrate the current findings into a unified framework, in which E3 ligases act as central regulatory nodes linking injury-induced molecular responses to chronic joint degeneration. Importantly, we emphasize the pharmacological and translational potential of targeting E3 ubiquitin ligases as a novel therapeutic strategy. Recent advances in small-molecule modulators, gene-based interventions, and proteolysis-targeting chimeras (PROTACs) highlight the druggability of this regulatory system and provide new opportunities for disease-modifying treatment in PTOA. We also discuss the current challenges, including context-dependent effects, limited PTOA-specific validation, and delivery barriers. Overall, this review provides a comprehensive and therapeutically oriented perspective on E3 ubiquitin ligases in PTOA and highlights their potential as promising targets for pharmacological intervention and disease-modifying therapy.